Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0220723 (
PCA
)
4,687
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
To assess the incidence of ERG rearrangements and
PTEN
deletions in a group of prognostically favorable
PCA
tumors of the transition zone (TZ). We interrogated 54 unsuspected
PCA
tumors using fluorescence in-situ hybridization for ERG rearrangements and
PTEN
deletions. ERG rearrangements were detected in 6/47 (12.7%) cases with 4/6 (66%) occurring by deletion.
PTEN
deletions were detected in 9/47 (19.1%) cases with only 3/47 (6.4%) having both
PTEN
losses and ERG rearrangements (p = 0.07). Only ERG rearrangements were associated with higher tumor volume > 5% (p = 0.04);
PTEN
deletions showed similar trends (p = 0.06). None of the markers showed association with Gleason score. In conclusion, although TZ and peripheral zone tumors share similar molecular etiologies, they exhibit differences in the rates of ERG and
PTEN
aberrations. The differences of ERG and /or
PTEN
genetic aberrations in TZ tumors may point toward a subset of tumors with adverse behavior. Additional studies implementing ERG and
PTEN
tissue-based FISH assays in tumors of the TZ are warranted to substantiate the potential clinical value of these biomarkers in the management of men with incidental
PCA
.
...
PMID:Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone. 2117 9
A wide array of molecular markers and genomic signatures, reviewed in this article, may soon be used as adjuncts to currently established screening strategies, prognostic parameters, and early detection markers. Markers of genetic susceptibility to
PCA
, recurrent epigenetic and genetic alterations, including ETS gene fusions,
PTEN
alterations, and urine-based early detection marker PCA3, are discussed. Impact of recent genome-wide assessment on our understanding of key pathways of
PCA
development and progression and their potential clinical implications are highlighted.
...
PMID:Molecular Updates in Prostate Cancer. 2661 15
Tibetan goat is an ancient breed, which inhabits the adverse conditions of the plateaus in China. To investigate the role of selection in shaping its genomes, we genotyped Tibetan goats (Nagqu Prefecture, above 4500 m) and three lowland populations (Xinjiang goats, Taihang goats and Huanghuai goats). The result of
PCA
, neighbor-joining (N-J) tree and model-based clustering showed that the genetic structure between the Tibetan goat and the three lowland populations has significant difference. As demonstrated by the
di
statistic, we found that some genes were related to the high-altitude adaptation of Tibetan goats. Functional analysis revealed that these genes were enriched in the VEGF (vascular endothelial growth factor) signaling pathway and melanoma, suggesting that nine genes (
FGF2
,
EGFR
,
AKT1
,
PTEN
,
MITF
,
ENPEP
,
SIRT6
,
KDR
, and
CDC42
) might have important roles in the high-altitude adaptation of Nagqu Tibetan goats. We also found that the
LEPR
gene was under the strongest selection (
di
value = 16.70), and it could induce upregulation of the hypoxic ventilatory response. In addition, five genes (
LEPR
,
LDB1
,
EGFR
,
NOX4
and
FGF2
) with high
di
values were analyzed using q-PCR. Among them, we found that
LEPR
,
LDB1
and
FGF2
exhibited higher expression in the lungs of the Tibetan goats;
LEPR
,
EGFR
and
LDB1
exhibited higher expression in the hearts of the Huanghuai goat. Our results suggest that
LEPR
,
LDB1
,
EGFR
and
FGF2
genes may be related to the high-altitude adaptation of the goats. These findings improve our understanding of the selection of the high-altitude adaptability of the Nagqu Tibetan goats and provide new theoretical knowledge for the conservation and utilization of germplasm resources.
...
PMID:Selection Signatures Analysis Reveals Genes Associated with High-Altitude Adaptation in Tibetan Goats from Nagqu, Tibet. 3291 23